Stem Cell Clinic

Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

By Stell Cell Research

SAN FRANCISCO, May 29, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced that management will participate in multiple upcoming healthcare conferences in June.

View original post here:
Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June

By Stell Cell Research

CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in two upcoming fireside chats in June:

Read the original:
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June

Fulcrum Therapeutics to Present at Upcoming Medical Meetings

By Stell Cell Research

CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced upcoming presentations at the 5th Global Congress on Sickle Cell Disease and the 2025 European Hematology Association Congress.

Continued here:
Fulcrum Therapeutics to Present at Upcoming Medical Meetings

Alumis to Present at the Jefferies Global Healthcare Investor Conference

By Stell Cell Research

SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that Martin Babler, President and Chief Executive Officer of Alumis, will present at the Jefferies Global Healthcare Conference on June 4, 2025 at 3:10 p.m. ET.

See the article here:
Alumis to Present at the Jefferies Global Healthcare Investor Conference

MediPharm Labs Responds to Fabricated Allegations from Dissident Shareholder

By Stell Cell Research

TORONTO, May 29, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE:MLZ) (“MediPharm” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoids, today confirmed that the Company is aware of the news release issued by Apollo Technology Capital Corporation (“Apollo”) on May 29, 2025 making baseless allegations of malfeasance against the Company.

Visit link:
MediPharm Labs Responds to Fabricated Allegations from Dissident Shareholder

Roche’s fenebrutinib maintains near-complete suppression of disease activity and disability progression for up to two years in people with relapsing…

By Stell Cell Research

Basel, 30 May 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new, 96-week data for fenebrutinib demonstrating that patients with relapsing multiple sclerosis (RMS) maintained no disability progression and low levels of disease activity for up to two years. The latest results for this investigational Bruton’s tyrosine kinase (BTK) inhibitor from the Phase II FENopta open-label extension (OLE) study were presented at the Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting in Phoenix, Arizona.

Visit link:
Roche’s fenebrutinib maintains near-complete suppression of disease activity and disability progression for up to two years in people with relapsing...

←